COMP <GO>
PTCT vs TVTX // FREE CASH FLOW YIELD
PTC Therapeutics Inc. (NASDAQ) VS. Travere Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PTCT 10
— TVTX 1
▲ FREE CASH FLOW YIELD LEADER: PTCT
LAST: $60.88 (+1.52%) • MKT CAP: $5.01B
fcf-yield
13.05%
LAST: $49.26 (-2.24%) • MKT CAP: $4.75B
fcf-yield
0.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTCT VS. TVTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTCT | TVTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | -13.00% | +98.00 | PTCT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 13.05% | 0.33% | +12.72 | PTCT | /fcf-yield <GO> |
| Operating Margin | 50.10% | -12.80% | +62.90 | PTCT | /operating-margins <GO> |
| Net Profit Margin | 39.50% | -5.20% | +44.70 | PTCT | /net-margins <GO> |
| Revenue Growth (YoY) | 114.50% | 110.50% | +4.00 | PTCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.73 | 3.44 | -1.71 | TVTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | PTCT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.2 | 35.8 | +7.40 | PTCT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.08 | +0.07 | PTCT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.6x | 18.0x | -11.40 | PTCT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.01B | $4.75B | $260.3M | PTCT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTCT REV | TVTX REV | PTCT GROSS % | TVTX GROSS % | PTCT FCF | TVTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.73B | $490.7M | — | 97.9% | $702.3M | $15.7M |
| FY 2024 | $806.8M | $233.2M | — | 96.7% | -$114.2M | -$248.0M |
| FY 2023 | $937.8M | $145.2M | — | — | -$200.6M | -$286.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTCT // BETA 1.15
TVTX // BETA 1.08